AZN Price Prediction Next Week
Analysis and Insights
To predict the stock price of AstraZeneca (AZN) for the next trading week, we analyze both news and technical indicators.
News Impact:
Positive Development: AstraZeneca is investing $2.5 billion in a new R&D center in Beijing, China, which is expected to enhance its growth prospects and strengthen its position in a key market.
Challenges in the UK: The UK pharmaceutical industry faces high levies, which could hinder investment and growth. AstraZeneca may be affected by these challenges, potentially impacting its global competitiveness.
Technical Analysis:
- RSI (14): 48.50 (Neutral)
- MACD: 0.91 (Bullish Signal Line Crossover)
- Fibonacci Levels: Resistance at 77.42, Support at 74.68
- Price Action: Trading near the 20-day moving average (76.29)
Price Prediction:
Given the positive news from China and the neutral technical indicators, AZN is expected to trade between 74.68 and 77.42. The stock may test the upper resistance level of 77.42 next week.
Recommendation:
Sell if the stock approaches the resistance level of 77.42, as it may face selling pressure. Consider Buy if it dips towards the support level of 74.68 with positive momentum.
AZN Similar Chart Price Prediction
The price of AZN is predicted to go up -0.23%, based on the high correlation periods with ASB. The similarity of these two price pattern on the periods is 94.03%.
AZN
ASB
Down: -0.23%Similarity: 94.03%
AZN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
AZN Price Forecast($)
Potential Return(%)
2025
75.000
13.210
2026
85.000
11.530
2027
95.000
24.660
2028
110.000
44.340
2029
120.000
57.460
2030
120.000
57.460
What is AZN stock price prediction 2025 ?
What is AZN stock price prediction 2026 ?
What is AZN stock price prediction 2027 ?
What is AZN stock price prediction 2028 ?
What is AZN stock price prediction 2029 ?
What is AZN stock price prediction 2030 ?
AZN Revenue Forecast
AZN EPS Forecast
AZN FAQs
What is AZN revenue forecast for next quarter？
What is AZN eps forecast for next quarter？
AZN VS S&P500
The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.
The management team is focusing the pipeline toward areas of high unmet medical need, which should increase the odds of success and bring strong pricing power for the new drugs.
AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects.
AZN Analyst's Forecast
Matthew Weston
UBS
Hold → Strong Buy
2025-02-13
Price Target
n/a
Downside
0%
UBS upgraded AstraZeneca to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company's "sector-leading pipeline potential" for the upgrade.
Matthew Weston
UBS
Strong Sell → Hold
2024-11-20
Price Target
n/a
Downside
0%
